Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 19/20 | 0.61 |
| ▸ | RARG | P13631 | 19/20 | 0.61 |
| ▸ | RARA | P10276 | 18/20 | 0.61 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239862 | 0.89 | RARA (0.49) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8664382 | 0.88 | RARB (0.44) | RARBRARGRARA | |
| SCHEMBL8682491 | 0.88 | RARA (0.46) | RARBRARGRARA | |
| SCHEMBL8682496 | 0.88 | RARA (0.46) | RARBRARGRARA | |
| SCHEMBL6818882 | 0.84 | RARB (0.48) | RARBRARGRARACYP26A1 | |
| SCHEMBL6238701 | 0.84 | RARA (0.60) | RARBRARGRARA | |
| SCHEMBL6238706 | 0.84 | RARA (0.60) | RARBRARGRARA | |
| SCHEMBL8981637 | 0.82 | RARA (0.60) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8901460 | 0.82 | RARB (0.67) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8901255 | 0.81 | RARB (0.63) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6319948-B2 | PREVENTION AND/OR MINIMIZATION OF SURGICAL ADHESION FORMATION BY ADMINISTERING CERTAIN SUBSTITUTED (5,6)-DIHYDRONAPHTHALENYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2001-11-20 | — | — | US | disclosed |
| US-20010003780-A1 | Retinoid antagonists and uses thereof | TRAMPOSCH KENNETH M (US) | 2001-06-14 | — | — | US | disclosed |
| WO-1998046228-A1 | RETINOID ANTAGONISTS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0853610-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan (US) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003780-A1 | Retinoid antagonists and uses thereof | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.